DMAPT decreases CD34 surface expression in canine studies. The percentage of CD34⁺ cells was determined for PB samples obtained at the indicated day of treatment (left panels, □). WBC counts for the same samples are shown in the right panels. The dose of DMAPT and day and route of administration are shown on the horizontal axis for each study. (A) Canine study case no. 1. (B) Case no. 2. (C) Case no. 3.